Current and emerging strategies in the management of venous thromboembolism: benefit–risk assessment of dabigatran

References

• SpencerFAEmeryCJoffeSWIncidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE studyJ Thromb Thrombolysis200928440140919629642
   PubMed Web of Science ®Google Scholar
• HeitJASilversteinMDMohrDNPettersonTMO’FallonWMMeltonLJPredictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort studyArch Intern Med2009159544545310074952
   PubMedGoogle Scholar
• HirshJGuyattGAlbersGWHarringtonRSchünemannHJAmerican College of Chest PhysiciansAntithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)Chest20081336 Suppl110S112S18574260
   PubMed Web of Science ®Google Scholar
• KearonCNatural history of venous thromboembolismCirculation200310723 Suppl 1122
   Google Scholar
• MayerRSStreiffMBHobsonDBHalpertDEBerenholtzSMEvidence-based venous thromboembolism prophylaxis is associated with a six-fold decrease in numbers of symptomatic venous thromboembolisms in rehabilitation inpatientsPM R20113121111111522192320
   PubMedGoogle Scholar
• CohenATTapsonVFBergmannJFENDORSE InvestigatorsVenous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional studyLancet2008371961038739418242412
   PubMed Web of Science ®Google Scholar
• KearonCAklEAComerotaAJAmerican College of Chest PhysiciansAntithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20121412 Suppl419S494S
   Web of Science ®Google Scholar
• AnsellJHirshJHylekEJacobsonACrowtherMPalaretiGPharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelinesChest20081336 Suppl160S198S18574265
   PubMed Web of Science ®Google Scholar
• EckmanMHRosandJGreenbergSMGageBFCost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillationAnn Intern Med20091502738319153410
   PubMed Web of Science ®Google Scholar
• PistersRLaneDANieuwlaatRde VosCBCrijnsHJLipGYA novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart surveyChest201013851093110020299623
   PubMed Web of Science ®Google Scholar
• OstDTepperJMiharaHLanderOHeinzerRFeinADuration of anticoagulation following venous thromboembolism: a meta-analysisJAMA2005294670671516091573
   PubMed Web of Science ®Google Scholar
• BudnitzDSLovegroveMCShehabNRichardsCLEmergency hospitalizations for adverse drug events in older AmericansN Engl J Med2011365212002201222111719
   PubMed Web of Science ®Google Scholar
• Falck-YtterYFrancisCWJohansonNAPrevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20121412 Suppl278S325S
   PubMed Web of Science ®Google Scholar
• HullRDPineoGFFrancisCLow-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in- hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin trial investigatorsArch Intern Med2000160142208221510904465
   PubMedGoogle Scholar
• GeertsWHBergqvistDPineoGFPrevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelinesChest20081336 Suppl381S453S18574271
   PubMed Web of Science ®Google Scholar
• WilkeTMoockJMüllerSPfannkucheMKurthANonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgeryClin Orthop Relat Res201046892437245320333493
   PubMed Web of Science ®Google Scholar
• WilkeTPatient preferences for an oral anticoagulant after major orthopedic surgery: results of a German surveyPatient200921394922273058
   PubMedGoogle Scholar
• EikelboomJWWeitzJINew anticoagulantsCirculation2010121131523153220368532
   PubMed Web of Science ®Google Scholar
• WeitzJINew oral anticoagulants: a view from the laboratoryAm J Hematol201287S1S133S13622407747
   PubMedGoogle Scholar
• StangierJRathgenKStähleHGansserDRothWThe pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBr J Clin Pharmacol200764329230317506785
   PubMed Web of Science ®Google Scholar
• BlechSEbnerTLudwig-SchwellingerEStangierJRothWThe metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humansDrug Metab Dispos200836238639918006647
   PubMed Web of Science ®Google Scholar
• EisertWGHauelNStangierJWienenWClemensAvan RynJDabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombinArterioscler Thromb Vasc Biol201030101885188920671233
   PubMed Web of Science ®Google Scholar
• WalengaJMAdiguzelCDrug and dietary interactions of the new and emerging oral anticoagulantsInt J Clin Pract201064795696720584229
   PubMed Web of Science ®Google Scholar
• Pradaxa^® (Dabigatran) Package InsertRidgefield, CTBoehringer Ingelheim Pharmaceuticals, Inc2013
   Google Scholar
• ErikssonBIDahlOERosencherNRE-MODEL Study GroupOral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trialJ Thromb Haemost20075112178218517764540
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOERosencherNRE-NOVATE Study GroupDabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trialLancet2007370959194995617869635
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOEHuoMHRE-NOVATE II Study GroupOral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: a randomised, double-blind, non-inferiority trialThromb Haemost2011105472172921225098
   PubMed Web of Science ®Google Scholar
• RE-MOBILIZE Writing Committee; GinsbergJSDavidsonBLOral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgeryJ Arthroplasty20092419
   PubMed Web of Science ®Google Scholar
• FriedmanRJDahlOERosencherNRE-MOBILIZE, REMODEL, RE-NOVATE Steering CommitteesDabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trialsThromb Res2010126317518220434759
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKRE-COVER Study GroupDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med2009361242342235219966341
   PubMed Web of Science ®Google Scholar
• SchulmanSKakkarAKGoldhaberSZRE-COVER II Trial InvestigatorsTreatment of thromboembolism with dabigatran or warfarin and pooled analysisCirculation2014129776477224344086
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKRE-SONATE Trial InvestigatorsExtended use of dabigatran, warfarin, or placebo in venous thromboembolismN Engl J Med2013368870971823425163
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSRE-LY Steering Committee and InvestigatorsDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSReillyPAWallentinLNewly identified events in the RE-LY trialN Engl J Med2010363191875187621047252
   PubMed Web of Science ®Google Scholar
• DouxfilsJBuckinxFMullierFDabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trialsJ Am Heart Assoc201433e00051524906369
   PubMed Web of Science ®Google Scholar
• UchinoKHernandezAVDabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trialsArch Intern Med2012172539740222231617
   PubMed Web of Science ®Google Scholar
• MakKHCoronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trialsBMJ Open201225e001592
   PubMed Web of Science ®Google Scholar
• University of Sao Paulo General HospitalEffects of LMWH versus dabigatran on platelet aggregation in patients with stable coronary artery diseaseClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)2000 [cited April 20, 2015]. Available from: http://clinicaltrials.gov/show/NCT02389582
   Google Scholar
• ThorneKMDeeSJayathissaSThrombotic events after discontinuing dabigatran: rebound or resumption?BMJ2012345e446922761096
   PubMedGoogle Scholar
• Van de WerfFBrueckmannMConnollySJA comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN)Am Heart J2012163693193722709744
   PubMed Web of Science ®Google Scholar
• MooreTJCohenMRMattisonDRDabigatran, bleeding, and the regulatorsBMJ2014349g451725056265
   PubMed Web of Science ®Google Scholar
• ReillyPALehrTHaertterSRE-LY InvestigatorsThe effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy)J Am Coll Cardiol201463432132824076487
   PubMed Web of Science ®Google Scholar
• van RynJStangierJHaertterSDabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activityThromb Haemost201010361116112720352166
   PubMed Web of Science ®Google Scholar
• van RynJGrottkeOSpronkHMeasurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assaysClin Lab Med201434347950125168938
   PubMed Web of Science ®Google Scholar
• HankeyGJEikelboomJWDabigatran etexilate: a new oral thrombin inhibitorCirculation2011123131436145021464059
   PubMed Web of Science ®Google Scholar
• HerrmannRPAssays for and reversal of new anticoagulantsClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)2000 [cited April 20, 2015]. Available from: http://clinicaltrials.gov/show/NCT01795781
   Google Scholar
• Van RynJRuehlDPriepkeHHauelNWienenWReversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIHaematologica200893Supple 1148
   Google Scholar
• EerenbergESKamphuisenPWSijpkensMKMeijersJCBullerHRLeviMReversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjectsCirculation2011124141573157921900088
   PubMed Web of Science ®Google Scholar
• SchieleFvan RynJNewsomeCA specific antidote for dabigatran: functional and structural characterizationBlood2013121183554356223476049
   PubMed Web of Science ®Google Scholar
• van RynJSchmollMPilluHEffect of Dabigatran on the Ability to Generate Fibrin At a Wound Site and its Reversal By Idarucizumab, the Antidote to Dabigatran, in Healthy Volunteers: An Exploratory Marker of Blood LossPresented on 1 8th November at the American Heart Association Scientific SessionsChicago, USA2014
   Google Scholar
• AgenoWGallusASWittkowskyAAmerican College of Chest PhysiciansOral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20121412 Suppl44S88S
   Web of Science ®Google Scholar
• StangierJRathgenKStähleHMazurDInfluence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilateClin Pharmacokinet201049425926820214409
   PubMed Web of Science ®Google Scholar
• KnaufFChaknosCMBernsJSPerazellaMADabigatran and kidney disease: a bad combinationClin J Am Soc Nephrol2013891591159723868901
   PubMed Web of Science ®Google Scholar
• ChangDNDagerWEChinAIRemoval of dabigatran by hemodialysisAm J Kidney Dis201361348748923219111
   PubMed Web of Science ®Google Scholar
• ChanKEEdelmanERWengerJBThadhaniRIMadduxFWDabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysisCirculation20151311197297925595139
   PubMed Web of Science ®Google Scholar
• RoldánVMarínFManzano-FernándezSThe HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillationJ Am Coll Cardiol201362232199220424055744
   PubMed Web of Science ®Google Scholar
• Capital District Health AuthorityAn evaluation of the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate in hemodialysis patientsClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)2000 [cited April 20, 2015]. Available from: http://clinicaltrials.gov/show/NCT01590823
   Google Scholar
• HarperPYoungLMerrimanEBleeding risk with dabigatran in the frail elderlyN Engl J Med2012366986486622375994
   PubMed Web of Science ®Google Scholar
• GeldhofVVandenbrieleCVerhammePVanasscheTVenous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulantsThromb J2014122125650285
   PubMed Web of Science ®Google Scholar
• GrahamDJReichmanMEWerneckeMCardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillationCirculation201413115716425359164
   PubMed Web of Science ®Google Scholar
• PrandoniPLensingAWPiccioliARecurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood20021830783083
   Google Scholar
• FargeDDebourdeauPBeckersMInternational clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancerJ Thromb Haemost2013111567023217107
   PubMed Web of Science ®Google Scholar
• SchulmanSGoldhaberSZKearonCTreatment with dabigatran or warfarin in patients with venous thromboembolism and cancerThromb Haemost Epub352015
   Web of Science ®Google Scholar